NDC product
Ciprofloxacin and dexamethasone
NDC 62756-427 · Sun Pharmaceutical Industries, Inc.
Key facts
| Product NDC | 62756-427 |
|---|---|
| Proprietary name | Ciprofloxacin and dexamethasone |
| Nonproprietary name | Ciprofloxacin and dexamethasone |
| Substances | CIPROFLOXACIN HYDROCHLORIDE, DEXAMETHASONE |
| Dosage form | SUSPENSION/ DROPS |
| Route | AURICULAR (OTIC) |
| Labeler | Sun Pharmaceutical Industries, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA210470 |
| Pharmacologic classes | Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Cytochrome P450 1A2 Inhibitors [MoA], Fluoroquinolone Antibacterial [EPC], Fluoroquinolones [CS] |
| Marketing start | Sep 1, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: